It essentially means can not act is if it was given full approval to use as open label for other indications. It’s already been established that EUA can charge and frankly CYDY not receiving any government grants or help can charge whatever they want. Also the criteria explained leronlimab would have already been given EUA for severe critical if it wasn’t involved in a Phase 3 trial in which company saw chance to capitalize on full approval with primary endpoint met vs relying of good faith of FDA to make fair decision on EUA. Every competitor has dropped out of the mortality reduction race. We won the race full approval or not EUA is days to weeks away.